Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.

McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD.

Pharmacoeconomics. 2018 May 8. doi: 10.1007/s40273-018-0658-x. [Epub ahead of print] Review.

PMID:
29736895
2.

Achieving high value care for all and the perverse incentives of 340B price agreements.

Whittington MD, Campbell JD, McQueen RB.

Neurol Clin Pract. 2018 Apr;8(2):148-152. doi: 10.1212/CPJ.0000000000000437.

3.

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England.

McQueen RB, Breton MD, Craig J, Holmes H, Whittington MD, Ott MA, Campbell JD.

J Diabetes Sci Technol. 2018 Sep;12(5):992-1001. doi: 10.1177/1932296818769098. Epub 2018 Apr 21.

PMID:
29681171
4.

A Call for Open-Source Cost-Effectiveness Analysis.

McQueen RB, Padula WV, Campbell JD.

Ann Intern Med. 2018 Apr 3;168(7):528-529. doi: 10.7326/L17-0694. No abstract available.

PMID:
29610902
5.

Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.

Whittington MD, McQueen RB, Campbell JD.

JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049. No abstract available.

PMID:
29554182
6.

Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine.

Padula WV, McQueen RB, Pronovost PJ.

Med Care. 2017 Nov;55(11):915-917. doi: 10.1097/MLR.0000000000000813.

PMID:
29028755
7.
8.

Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes.

Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1071-1081.e9. doi: 10.1016/j.jaip.2017.01.004. Epub 2017 Mar 9.

PMID:
28286157
9.

Economic burden of comorbid chronic kidney disease and diabetes.

McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ.

J Med Econ. 2017 Jun;20(6):585-591. doi: 10.1080/13696998.2017.1288127. Epub 2017 Feb 14.

PMID:
28128669
10.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD.

Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. doi: 10.1016/j.anai.2016.10.028. Epub 2016 Dec 4.

PMID:
27923549
11.

Value of Information in Asia: Concepts, Current Use, and Future Directions.

Dilokthornsakul P, McQueen RB, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD.

Value Health Reg Issues. 2016 May;9:99-104. doi: 10.1016/j.vhri.2015.12.003. Epub 2016 Apr 12.

PMID:
27881269
12.

Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up.

Price DB, van Boven JF, Law LM, Cifra A, McQueen RB.

Multidiscip Respir Med. 2016 Nov 2;11:39. eCollection 2016.

13.

COPD case finding: effective, but also cost-effective?

van Boven JF, McQueen RB, Price DB.

Lancet Respir Med. 2016 Oct;4(10):e49. doi: 10.1016/S2213-2600(16)30266-1. No abstract available.

PMID:
27707463
14.

Incremental increases in economic burden parallels cardiometabolic risk factors in the US.

McQueen RB, Ghushchyan V, Olufade T, Sheehan JJ, Nair KV, Saseen JJ.

Diabetes Metab Syndr Obes. 2016 Aug 2;9:233-41. doi: 10.2147/DMSO.S106809. eCollection 2016.

15.

Incorporating real-world clinical practice in multiple sclerosis economic evaluations.

McQueen RB, Nair KV, Vollmer TL, Campbell JD.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):869-72. doi: 10.1586/14737167.2015.1081060. Epub 2015 Aug 20.

PMID:
26295727
16.

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada.

McQueen RB, Breton MD, Ott M, Koa H, Beamer B, Campbell JD.

J Diabetes Sci Technol. 2015 Aug 14;10(2):366-77. doi: 10.1177/1932296815599551.

17.

Capsule Commentary on Duru et al., Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).

McQueen RB.

J Gen Intern Med. 2015 Nov;30(11):1697. doi: 10.1007/s11606-015-3296-4. No abstract available.

18.

Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.

McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD.

J Manag Care Spec Pharm. 2015 Mar;21(3):210-8b.

19.

Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information.

Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A.

Med Decis Making. 2015 Jul;35(5):596-607. doi: 10.1177/0272989X14556510. Epub 2014 Oct 27.

PMID:
25349188
20.

Frequency of Continuous Glucose Monitoring Use and Change in Hemoglobin A1C for Adults with Type 1 Diabetes in a Clinical Practice Setting.

McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Campbell JD.

Endocr Pract. 2014 Oct;20(10):1007-15. doi: 10.4158/EP14027.OR.

PMID:
24793924
21.

Fasting blood glucose--a missing variable for GFR-estimation in type 1 diabetes?

Bjornstad P, McQueen RB, Snell-Bergeon JK, Cherney D, Pyle L, Perkins B, Rewers M, Maahs DM.

PLoS One. 2014 Apr 29;9(4):e96264. doi: 10.1371/journal.pone.0096264. eCollection 2014.

22.

The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence.

Campbell JD, McQueen RB, Briggs A.

Ann Am Thorac Soc. 2014 Feb;11 Suppl 2:S105-11. doi: 10.1513/AnnalsATS.201309-295RM.

PMID:
24559022
23.

Association between glycated hemoglobin and health utility for Type 1 diabetes.

McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD.

Patient. 2014;7(2):197-205. doi: 10.1007/s40271-014-0045-4.

PMID:
24458545
24.

Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.

Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.

Am J Manag Care. 2013 Apr;19(4):278-85.

25.

Economic differences in direct and indirect costs between people with epilepsy and without epilepsy.

Libby AM, Ghushchyan V, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD.

Med Care. 2012 Nov;50(11):928-33. doi: 10.1097/MLR.0b013e31826c8613.

PMID:
23047781
26.

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap.

Page RL 2nd, Ghushchyan V, Allen RR, Roper L, Beck D, Jonathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV.

Drug Healthc Patient Saf. 2012;4:67-74. doi: 10.2147/DHPS.S32473. Epub 2012 Jul 10.

27.

Prescription ergocalciferol dosing for vitamin D repletion: a retrospective evaluation.

Vande Griend JP, McQueen RB, Linnebur SA, Vondracek SF.

Pharmacotherapy. 2012 Feb;32(2):135-41. doi: 10.1002/PHAR.1052.

PMID:
22392422
28.

An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures.

Pesa JA, Van Den Bos J, Gray T, Hartsig C, McQueen RB, Saseen JJ, Nair KV.

Patient Prefer Adherence. 2012;6:63-72. doi: 10.2147/PPA.S28396. Epub 2012 Jan 18.

29.

Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes.

McQueen RB, Ellis SL, Campbell JD, Nair KV, Sullivan PW.

Cost Eff Resour Alloc. 2011 Sep 14;9:13. doi: 10.1186/1478-7547-9-13.

30.

Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.

Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N.

Expert Rev Neurother. 2011 Jun;11(6):787-98. doi: 10.1586/ern.11.67.

PMID:
21651327
31.

Understanding barriers to medication adherence in the hypertensive population by evaluating responses to a telephone survey.

Nair KV, Belletti DA, Doyle JJ, Allen RR, McQueen RB, Saseen JJ, Vande Griend J, Patel JV, McQueen A, Jan S.

Patient Prefer Adherence. 2011 Apr 29;5:195-206. doi: 10.2147/PPA.S18481.

32.

Economic grand rounds: psychological distress and depression associated with job loss and gain: the social costs of job instability.

Libby AM, Ghushchyan V, McQueen RB, Campbell JD.

Psychiatr Serv. 2010 Dec;61(12):1178-80. doi: 10.1176/ps.2010.61.12.1178.

PMID:
21123399

Supplemental Content

Loading ...
Support Center